<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600492</url>
  </required_header>
  <id_info>
    <org_study_id>Riociguat-CTEPH</org_study_id>
    <nct_id>NCT04600492</nct_id>
  </id_info>
  <brief_title>THERAPY-HYBRID-BPA Trial</brief_title>
  <official_title>The Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in CTEPH Patients After Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hospital Organization Okayama Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Yakuhin, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Hospital Organization Okayama Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Riociguat could improve the exercise capacity and residual symptoms in patients with chronic&#xD;
      thromboembolic pulmonary hypertension (CTEPH) even after normalization of pulmonary arterial&#xD;
      pressure by balloon pulmonary angioplasty (BPA). This randomized controlled trial study aimed&#xD;
      to clarify whether the improvement of peak cardiac index (CI) during exercise maintains or&#xD;
      not between the riociguat continued group and the riociguat discontinued group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CTEPH is a disease that causes progressive pulmonary hypertension due to stenoses or&#xD;
      occlusions in the pulmonary artery due to an organized thrombus. And this is a disease that&#xD;
      results in right heart failure and death unless early diagnosis and appropriate treatment are&#xD;
      performed. Pulmonary endarterectomy (PEA), which surgically removes the intimal thrombus, has&#xD;
      been established as the treatment of choice for CTEPH. In the AHA/ACC guideline and ESC&#xD;
      guideline, PEA for CTEPH is class IC (1). In 2014, a soluble guanylate cyclase stimulant&#xD;
      (generic name: riociguat), which is one of the therapeutic agents for pulmonary hypertension,&#xD;
      was approved for patients with CTEPH who are ineligible for PEA, and residual pulmonary&#xD;
      hypertension after PEA (2). In addition, it has been reported that BPA, which is a catheter&#xD;
      interventional treatment, is also effective to improve hemodynamics in inoperable patients&#xD;
      with CTEPH (3, 4). However, some patients have residual symptoms such as dyspnea on exertion&#xD;
      even after normalization in hemodynamics by BPA. A randomized control study should be done to&#xD;
      confirm the necessary of continuation of riociguat for such patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 16, 2020</start_date>
  <completion_date type="Anticipated">January 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A double-blind, placebo-controlled study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>A double-blind, placebo-controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak CI change</measure>
    <time_frame>from baseline to 16 weeks</time_frame>
    <description>Change in Peak CI during the cardiopulmonary exercise test (CPET)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Active Comparator: Active drug group Riociguat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riociguat 0.5mg、1.0mg、2.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0.5mg、1.0mg、2.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat Oral Tablet</intervention_name>
    <description>Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo</description>
    <arm_group_label>Active Comparator: Active drug group Riociguat</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who meet CTEPH diagnostic criteria (complying with 2017 Japanese&#xD;
             Cardiovascular Society Guidelines diagnostic criteria)&#xD;
&#xD;
          2. Patients with diagnosed as a contraindication of pulmonary endarterectomy by an&#xD;
             experienced surgeon in the central diagnosis&#xD;
&#xD;
          3. Patients who were adjusted to reach the appropriate dose of riociguat within 8 weeks&#xD;
             and were able to continue riociguat thereafter&#xD;
&#xD;
          4. Patients who underwent BPA once or more after the dose adjustment of riociguat&#xD;
&#xD;
          5. Patients who have been able to continue taking the same dose of riociguat for more&#xD;
             than 3 months&#xD;
&#xD;
          6. Patients who can obtain written informed consent from the patients and legal&#xD;
             representatives&#xD;
&#xD;
          7. Patients with WHO functional class II or III at the time of the allocation&#xD;
&#xD;
          8. Over the age of 18 and under 85 at the time of obtaining informed consent&#xD;
&#xD;
          9. Patients with the resting CI value of less than 3.0 L/min/m2 in the right heart&#xD;
             catheterization test immediately before the allocation&#xD;
&#xD;
         10. Patients with the mean pulmonary artery pressure less than 25 mmHg in a right heart&#xD;
             catheterization test immediately before the allocation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are eligible for pulmonary endarterectomy (PEA)&#xD;
&#xD;
          2. Patients with pulmonary hypertension other than class 4 by NICE classification&#xD;
&#xD;
          3. Patients having difficulty in performing cardiopulmonary exercise test (CPET)&#xD;
&#xD;
          4. Patients with severe right heart failure requiring cardiotonic drugs&#xD;
&#xD;
          5. Patients with severe heart disease&#xD;
&#xD;
          6. Patients with severe liver damage&#xD;
&#xD;
          7. Patients with systolic blood pressure less than 90 mmHg at the screening&#xD;
&#xD;
          8. Patients with shunt disease&#xD;
&#xD;
          9. Patients with severe renal dysfunction (CCr &lt; 15 mL/min) requiring hemodialysis&#xD;
&#xD;
         10. Patients with life expectancy less than 2 years&#xD;
&#xD;
         11. Being pregnant or lactating&#xD;
&#xD;
         12. Patients who are contraindicated for riociguat&#xD;
&#xD;
         13. Patients using other unlicensed drugs&#xD;
&#xD;
         14. Patients who used pulmonary vasodilators within 4 weeks after obtaining the informed&#xD;
             consent of the right heart catheterization test.&#xD;
&#xD;
         15. Patients whom the investigator determines that the participation in this study is&#xD;
             inappropriate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka Ito</last_name>
    <role>Study Director</role>
    <affiliation>National Hospital Organization Nagoya Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiroto Shimokawahara, MD,PhD</last_name>
    <phone>+81-86-294-9911</phone>
    <email>hiroto.shimokk@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yutaka Ito</last_name>
    <phone>+81-52-951-1111</phone>
    <phone_ext>2493</phone_ext>
    <email>study.office@nnh.go.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Hospital Org anization Okayama Medical Center</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroto Shimokawahara, MD,PhD</last_name>
      <phone>+81-86-294-9911</phone>
      <email>hiroto.shimokk@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Miki Yanagihara</last_name>
      <phone>+81-86-294-9911</phone>
      <email>okmc-iec@nifty.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.</citation>
    <PMID>26320113</PMID>
  </reference>
  <reference>
    <citation>Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657.</citation>
    <PMID>23883377</PMID>
  </reference>
  <reference>
    <citation>Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012 Dec;5(6):748-55. doi: 10.1161/CIRCINTERVENTIONS.112.971077. Epub 2012 Nov 27.</citation>
    <PMID>23192917</PMID>
  </reference>
  <reference>
    <citation>Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y, Ando M, Fukuda K, Yoshino H, Satoh T. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012 Dec;5(6):756-62. doi: 10.1161/CIRCINTERVENTIONS.112.971390. Epub 2012 Nov 6.</citation>
    <PMID>23132237</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Thromboembolic Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riociguat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

